We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Medical News & Perspectives

JAMA. 1990;264(10):1225-1234. doi:10.1001/jama.1990.03450100013001.
Text Size: A A A
Published online


New Antirejection Drugs Anticipated  TRANSPLANTATION is rapidly approaching a "postcyclosporine era," just 7 years after this potent immunosuppressive drug launched transplantation from experimental science into mainstream medicine.Recently, several new compounds—molecular daughters and granddaughters of cyclosporine—have proven in animal models to be safe and even more potent and effective than cyclosporine. Three in particular—FK506 (Fujisawa Pharmaceutical Co, Tsukuba, Japan), RS-61443 (Syntex Corp, Palo Alto, Calif), and rapamycin (Wyeth-Ayerst Laboratories, Philadelphia, Pa)—drew attention at the International Congress of the Transplantation Society in San Francisco, Calif last month.Most exciting was the evidence that these drugs act at different stages along the rejection pathway, including the stimulation and proliferation of lymphocytes and the production of antibodies. They appear to work synergistically with each other and with cyclosporine, with one notable exception: the toxic combination of FK506 and cyclosporine. It is hoped the additive effect of these drugs in low concentrations


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.